Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I am amused by those who deny Sorrento could achieve a buyout share price of $200 or $300. What timelines are they looking at? How about a year or two from now? The progress of Sofusa and RTX emphasize that Sorrento is not only a Covid company. Sorrento also has potential blockbuster pain and cancer portfolios! Here are 32 Reasons my price target right now is $100+. Many can occur in the next 3-4 weeks.
1. PSS lawsuit worth $1.2 Billion+ potential out of court settlement
2. BARDA funding, other government funding
3.CYNK-001 NK FDA Phase 1/Phase 2 Trial data with Celularity (Sorrento has 25% stake)
4. STI-4398 (COVIDTRAP) FDA Phase 1 clinical trial
5. STI-1499 (COVIGUARD)FDA IND approval(DONE)
6. COVISHIELD(Therapeutic cocktail in partnership with Mt. Sinai Hospital) FDA IND application
7. Preclinical, peer reviewed data publication on STI-1499 and STI-4398 from UTMB, Dr. Slobodan Paessler (anytime now).
8. I-Cell COVID 19 Vaccine IND approval
9. Sorrento and SmartPharm gene encoded vaccine IND application
10. Sorrento and MabPharma ACE MAB IND approval
11. Phase 1 trial data of CD 38 for Amyloidosis
12. SP-102 phase 3 results
13. CD38 lymphoma IND
14. RTX arthritis news
15. RTX knee pain news
16. RTX cancer pain news(DONE)
17. RTX ARDS treatment
18. Scilex potential IPO
19. FDA approval of COVI-TRACK
20. Sales begin for COVI-TRACK
21. Several cancer trials with first-in-class DAR-T are coming
22. Abivirtinib phase 2 in Covid
23. Water soluble CBD partnership
24. Covid T-VIVA-19 Vaccine enters clinic
25. COVI-TRACE saliva test enters clinic
26. COVI-TRACE gains approval
27. SOFUSA delivery phase 1b cancer trial
28. SOFUSA delivery Enbril RA trial(DONE)
29. Analysts target prices are increasing steadily. $30 is latest
30. Institutions are buying. Up from 18% to 25%
31. Insiders holding solid at 34%
32. Mayo Clinic technology advances in clinic
Sorrento is increasingly being seen as a leader in Covid, non-opioid pain and cancer technologies. It is a small pharma with a large pharma portfolio. There's a lot of room for partnerships and growing value for a buyout. The SmartPharm and Mayo Clinic technologies add enormous value! Big pharmas with emptying portfolios will be attracted by a fistful of potential blockbusters!
The progress of Sofusa and RTX emphasize that Sorrento is not only a Covid company. Sorrento also has potential blockbuster pain and cancer portfolios! Here are 32 Reasons my price target is $100+.Many can occur in next 3-4 weeks.
1. PSS lawsuit worth $1.2 Billion+ potential out of court settlement
2. BARDA funding, other government funding
3.CYNK-001 NK FDA Phase 1/Phase 2 Trial data with Celularity (Sorrento has 25% stake)
4. STI-4398 (COVIDTRAP) FDA Phase 1 clinical trial
5. STI-1499 (COVIGUARD)FDA IND approval(DONE)
6. COVISHIELD(Therapeutic cocktail in partnership with Mt. Sinai Hospital) FDA IND application
7. Preclinical, peer reviewed data publication on STI-1499 and STI-4398 from UTMB, Dr. Slobodan Paessler (anytime now).
8. I-Cell COVID 19 Vaccine IND approval
9. Sorrento and SmartPharm gene encoded vaccine IND application
10. Sorrento and MabPharma ACE MAB IND approval
11. Phase 1 trial data of CD 38 for Amyloidosis
12. SP-102 phase 3 results
13. CD38 lymphoma IND
14. RTX arthritis news
15. RTX knee pain news
16. RTX cancer pain news(DONE)
17. RTX ARDS treatment
18. Scilex potential IPO
19. FDA approval of COVI-TRACK
20. Sales begin for COVI-TRACK
21. Several cancer trials with first-in-class DAR-T are coming
22. Abivirtinib phase 2 in Covid begins in August
23. Water soluble CBD partnership
24. Covid T-VIVA-19 Vaccine enters clinic
25. COVI-TRACE saliva test enters clinic
26. COVI-TRACE gains approval
27. SOFUSA delivery phase 1b cancer trial
28. SOFUSA delivery Enbril RA trial(DONE)
29. Analysts target prices are increasing steadily. $30 is latest
30. Institutions are buying. Up from 18% to 25%
31. Insiders holding solid at 34%
32. Mayo Clinic technology advances in clinic
Sorrento is increasingly being seen as a leader in Covid, non-opioid pain and cancer technologies. It is a small pharma with a large pharma portfolio. There's a lot of room for partnerships and growing value for a buyout. The SmartPharm and Mayo Clinic technologies add enormous value! Big pharmas with emptying portfolios will be attracted by a fistful of potential blockbusters!
Testing Sofusa delivery of Enbrel to treat Rheumatoid Arthritis...
https://clinicaltrials.gov/ct2/show/NCT04559412?term=Sorrento&draw=2&rank=1
What if Covi-Guard(1499) is not only the BEST but also the FIRST Covid antibody therapy approved? From the article below.
"The global spread of coronavirus has meant an increased focus on pharmaceutical companies that are developing Covid-19 related products, Sorrento being one of them with its COVI-Guard antibody. The recent development of FDA nod for phase 1 trial is important for Sorrento, with its objective to expand the study to a large trial and potentially apply for emergency use authorization from the U.S. FDA. Now, the company in a press release stated that its application for EUA can be as early as December. The other companies developing the antibody are expected to file for regulatory nod only towards the end of Q4 or later next year. If Sorrento were to be the first company with its antibody in the market via EUA, it would result in a meaningful appreciation in the stock price from the current levels, in our view. That said, the investors willing to take such risk should also weigh in the possibility of the company not able to secure the EUA."
https://www.google.com/amp/s/www.forbes.com/sites/greatspeculations/2020/09/21/sorrento-therapeutics-stock-is-an-interesting-pick-at-9/amp/
31 Reasons my price target is $100+.Many can occur in next 3-4 weeks.
1. PSS lawsuit worth $1.2 Billion+ potential
2. BARDA funding, other government funding
3.CYNK-001 NK FDA Phase 1/Phase 2 Trial data with Celularity (Sorrento has 25% stake)
4. STI-4398 (COVIDTRAP) FDA Phase 1 clinical trial
5. STI-1499 (COVIGUARD)FDA IND approval(DONE)
6. COVISHIELD(Therapeutic cocktail in partnership with Mt. Sinai Hospital) FDA IND application
7. Preclinical, peer reviewed data publication on STI-1499 and STI-4398 from UTMB, Dr. Slobodan Paessler (anytime now).
8. I-Cell COVID 19 Vaccine IND approval
9. Sorrento and SmartPharm gene encoded vaccine IND application
10. Sorrento and MabPharma ACE MAB IND approval
11. Phase 1 trial data of CD 38 for Amyloidosis
12. SP-102 phase 3 results
13. CD38 lymphoma IND
14. RTX arthritis news
15. RTX knee pain news
16. RTX cancer pain news
17. RTX ARDS treatment
18. Scilex potential IPO
19. FDA approval of COVI-TRACK
20. Sales begin for COVI-TRACK
21. Several cancer trials with first-in-class DAR-T are coming
22. Abivirtinib phase 2 in Covid begins in August
23. Water soluble CBD partnership
24. Covid T-VIVA-19 Vaccine enters clinic
25. COVI-TRACE saliva test enters clinic
26. COVI-TRACE gains approval
27. SOFUSA delivery phase 1b cancer trial
28. Analysts target prices are increasing steadily. $30 is latest
29. Institutions are buying. Up from 18% to 26% this week alone
30. Insiders holding solid at 34%
31. Mayo Clinic technology advances in clinic
Sorrento is increasingly being seen as a leader in Covid, non-opioid pain and cancer technologies. It is a small pharma with a large pharma portfolio. There's a lot of room for partnerships and growing value for a buyout. The SmartPharm and Mayo Clinic technologies add enormous value! Big pharmas with emptying portfolios will be attracted by a fistful of potential blockbusters!
From that Sept. 18 article: "We decided to align with Sorrento because of their capabilities around developing engineered T cells and their capacity around manufacturing. We created a working plan on how we would approach the emerging COVID-19 threat together. That’s how it started."
In a few months Sorrento may change what happens when Covid patients are hospitalized.
EARLY THERAPY: Covi-Guard (1499) neutralising antibody can clear Covid virus in 4 days safely and effectively according to preclinical studies.
RESCUE THERAPY: Abivirtinib can prevent or treat cytokine storm. It has been used safely in over 600 cancer patients. For that reason it will start with a Phase 2 trial.
Both of these technologies will be tested in the US and Brazil, two of the world's Covid hot-spots. Look for rapid approvals around the world.
Covi-Guard 1499 Phase 1 trial is basically for safety as are all phase 1 trials. But get ready to hear excellent efficacy results even on the lowest doses as that is what was seen in the preclinical studies. THE BEST ANTIBODY WILL BE A BLOCKBUSTER. Sorrento says they have it. These trials will proceed rapidly. We shall soon know. Lots of patients lives can be saved in US and Brazil!
The news has started to come! More on the way.
1. COVI-GUARD 1499 antibody enters clinic in US and Brazil (DONE)
2. COVI-TRACK 8 minute antibody test kit approval and marketing partnership
3. COVI-TRACE 30 minute virus saliva test kit approval
4. Celularity reports good interim phase 1/2 results (Sorrento owns 25%)
5. COVI-SHIELD triple antibody enters clinic
6. T-VIVA-19 vaccine enters clinic
7. Abivirtinib cytokine storm trial phase 2 enters clinic
8. Preclinical, peer reviewed data publication on STI-1499 and STI-4398 from UTMB, Dr. Slobodan Paessler (anytime now).
9. Sorrento/SmartPharm antibody vaccine enters clinic
10. Federal grants $500+ million
11. PSS decides to agree to $1.2 billion out of court settlement
12. Mayo Clinic drugs proceed in clinic.
13.Analysts upgrade from current $24 price target (DONE.) Now $30 and rises as each catalyst is announced)
What is the Mayo Clinic?
"MAYO CLINIC is "one of the largest not-for-profit, academic health systems in the U.S., with $14 billion in annual revenues and 65,000 employees. With a focus on caring for patients with serious, complex illnesses, Mayo Clinic operates in five states and cares for more than one million people a year, from all 50 states and nearly 140 countries. Mayo Clinic is ranked #1 in the nation by U.S. News and World Report."
Along with Mt.Sinai and Columbia University...another first rate partner!
More great scientific news ! Aquisition of Abivirtinib , SmartPharm and now this Mayo Clinic breakthrough technology. Sorrento is developing great synergies for its huge Antibody library.
"“The Mayo Clinic-developed ADNIC platform is a perfect fit for our extensive G-MAB antibody products including but not limited to our anti-PD-L1, anti-CD38, anti-BCMA and anti-ROR1 antibodies. We will accelerate the development and commercialization of this amazing technology by generating and developing multiple next-generation ADNIC product candidates for the potential treatment of cancer, COVID-19 and other human diseases,” stated Henry Ji, Ph.D., Chairman and CEO of Sorrento Therapeutics. “Teaming with Mayo Clinic, this license expands Sorrento’s mission of developing innovative life-saving medicines for unmet medical needs,” continued Dr. Ji. Sorrento will continue to execute on the clinical development strategy developed by Mayo Clinic for multiple ADNIC lead product candidates in COVID-19 and multiple solid and hematologic malignancies.'
How many events will occur before Annual Meeting Oct. 16?
1. PSS lawsuit worth $1.2 Billion+ potential
2. BARDA funding, other government funding
3.CYNK-001 NK FDA Phase 1/Phase 2 Trial interim data with Celularity (Sorrento has 25% stake)
4. STI-4398 (COVIDTRAP) FDA Phase 1 clinical trial
5. STI-1499 (COVIGUARD)FDA IND approval
6. COVISHIELD(Therapeutic cocktail in partnership with Mt. Sinai Hospital) FDA IND application
7. Preclinical, peer reviewed data publication on STI-1499 and STI-4398 from UTMB, Dr. Slobodan Paessler (anytime now).
8. I-Cell COVID 19 Vaccine IND approval
9. Sorrento and SmartPharm gene encoded vaccine IND application
10. Sorrento and MabPharma ACE MAB IND approval
11. Phase 1 trial data of CD 38 for Amyloidosis
12. SP-102 phase 3 results
13. CD38 lymphoma IND
14. RTX arthritis news
15. RTX knee pain news
16. RTX cancer pain news
17. RTX ARDS treatment
18. Scilex potential IPO
19. FDA approval of COVI-TRACK
20. Sales begin for COVI-TRACK
21. Several cancer trials with first-in-class DAR-T are coming
22. Abivirtinib phase 2 in Covid begins in August
23. Water soluble CBD partnership
24. Covid T-VIVA-19 Vaccine enters clinic
25. COVI-TRACE saliva test enters clinic
26. COVI-TRACE gains approval
27. SOFUSA delivery phase 1b cancer trial
28. Analysts target prices are increasing steadily. $30 is latest
29. Institutions are buying. Up from 18% to 25%
30. Insiders holding solid at 34%
Here's why Abivirtinib is needed. US and Brazilian studies could start next week!
"Among patients with moderate COVID-19, those randomized to a 10-day course of remdesivir did not have a statistically significant difference in clinical status compared with standard care at 11 days after initiation of treatment. Patients randomized to a 5-day course of remdesivir had a statistically significant difference in clinical status compared with standard care, but the difference was of uncertain clinical importance.
D. Brainard, MD, et.al., JAMA. Published online August 21, 2020. doi:10.1001/jama.2020.16349"
Insider Financial on Sorrento REASONS TO BE BULLISH ON SORRENTO STOCK
ByAlex Carlson: Posted on September 11 2020
We are going to try and spell into out for the bears on why it’s suicidal to be short Sorrento stock. Unfortunately, we cannot use small words that they would understand with their limited intellect, but we will try.
First, the key to understanding Sorrento stock is realizing that at its heart, it’s an antibody company. An antibody is a protective protein produced by the immune system in response to the presence of a foreign substance. Cancer cells, bacteria, and viruses, like the one that causes COVID-19, are foreign substances and therefore, theoretically can be impeded or neutralized by antibodies. A vaccine is meant to safely expose a person’s body to a pathogen to teach it to create these neutralizing antibodies. Sorrento’s approach skips the need to teach the body and introduces the neutralizing antibodies directly in vivo. This allows the approach to be administered to healthy and infected people alike.
Second, Sorrento stock is acquiring Cambridge, MA-based SmartPharm Therapeutics, a developer of non-viral DNA and RNA gene delivery platforms for COVID-19 and rare diseases. The company plans to accelerate the development of multiple candidates for in vivo gene-encoded expression of Sorrento antibodies, starting with COVID-19 “cure” STI-1499. It says SmartPharm’s Gene Mab platform enables intramuscular delivery of low-immunogenic DNA plasmid-encoded with a therapeutic antibody for long-lasting expression.
Third, Sorrento stock has a licensing pact with Columbia University for the rights to a rapid one-step diagnostic test that detects the SARS-CoV-2 virus in as little as 30 minutes from a saliva sample. The test developed by Columbia’s team, to be marketed by Sorrento under the COVI-TRACE name, holds all of the testing materials in a single tube and requires no specialized laboratory equipment, making it easily deployable for point-of-care, on-site, or potentially at-home testing.
Fourth, its COVI-TRACK test could drive substantial upside. In order to conduct analytical validation, sample cohorts from healthy donors and COVID-19 patient samples were tested, with the assay showing specificity of over 97% and diagnostic sensitivity of more than 94%. Upon issuance of an EUA, the COVI-TRACK test will be available for distribution to clinical testing sites nationwide. Sorrento has secured manufacturing capacity to support the production of up to five million test kits per month.
Fifth, SRNE has evaluated billions of antibodies and identified a small group that can block the S1 protein’s interaction with human angiotensin-converting enzyme 2 (ACE2), the receptor used for viral entrance into human cells. The hope is that the cocktail will remain effective even if the virus mutates.
Sixth, Sorrento plans to accelerate the development of multiple candidates for in vivo gene-encoded expression of Sorrento’s antibodies, starting with Sorrento’s previously announced STI-1499, or COVI-GUARD, which is currently moving through preclinical and manufacturing requirements with an IND submission targeted for this month.
Seventh, the company’s stake in ImmuneOncia, a clinical-stage immuno-oncology-centric biopharmaceutical company established in 2016 as a joint venture company between Yuhan and Sorrento Therapeutics. Last month, Samsung Biologics (207940.KS) and ImmuneOncia Therapeutics have a partnership to develop and manufacture five candidate molecules, expanding upon the two companies’ existing CDO partnership first established in 2018.
Eighth, Sorrento Therapeutics has turned down at least three takeover offers that we are aware of.
Ninth, the shorts are short 24% of the float or $1 billion at today’s prices. The short squeeze will continue as the shorts cannot withstand losses in the billions.
Tenth, Chairman, CEO, and President Henry Ji, Ph.D. just pulled an Elon Musk and is set for a huge payday. He will earn options to purchase up to ~24.9M shares at $17.30 representing a 10% stake in the company if fully exercised. The award vests in 10 equal tranches starting with ~2.5M options if the company’s market cap reaches $5B. The 10th and last tranche vests if the company’s value hits $35B. Assuming full vestment and no further equity offerings, his total award will be potentially worth ~$3.3B.
Eleventh, Wall Street analysts remain bullish. H.C. Wainwright has a price target of $30 on Sorrento stock and Dawson James has a $24 target. We expect these price targets to keep getting raised as Sorrento stock looks set to continue its bull run.
BOTTOM LINE
These are just eleven reasons off the top of our head that we can think of on why to be bullish on Sorrento stock. However, we left out the biggest one and one which we believe is highly likely – funding from Operation Warp Speed. Funding from the U.S. government would send Sorrento stock flying and put the company on the fast track to commercialization. We believe this is where things are heading and why Chairman, CEO, and President Henry Ji, Ph.D. has no issues taking options at $17.30 a share. He realizes that even with the tremendous run we’ve seen in Sorrento stock so far this year, the rally could just be getting started.
As always, good luck to all (except the shorts)
Dr.Ji is a genius. Proof? His acquisition of Abivirtinib ... followed by the acquisition of SmartPharm! Both have blockbuster implications for Covid, but even greater long term implications for cancer. Both will turn out to be multi-blockbusters. I have great confidence in his scientific insights. Trust the science!
Great analysis from Insider Financial...
By Alex Carlson Posted on September 05 2020
We hate to keep patting ourselves on the back as we have become a thorn in the short’s side with our market calls, but it is one of life’s great joys watching the shorts get slaughtered in Sorrento stock. Although, we did warn them. We said on June 17th that Sorrento stock was going to squeeze the shorts, which you can read here. We followed up a month later on July 15th and said that new highs were coming, which you can read here. We have nailed every move in Sorrento stock and the rally is far from over. Matter of fact, if you look at the charts of Novovax and Moderna, the rally in Sorrento stock could just be getting started.
ABOUT SORRENTO STOCK
First up, here’s a little background info for those not familiar with Sorrento stock. Sorrento is antibody-centric and leverages its proprietary G-MAB™ library and targeted delivery modalities to generate the next generation of cancer therapeutics. These modalities include proprietary chimeric antigen receptor T-cell therapy (“CAR-T”), dimeric antigen receptor T-cell therapy (“DAR-T”), antibody-drug conjugates (“ADCs”) as well as bispecific antibody approaches. The Company also has programs assessing the use of its technologies and products in autoimmune, inflammatory, viral, and neurodegenerative diseases.
Outside of immuno-oncology programs, as part of the Company’s global aim to provide a wide range of therapeutic and diagnostic products to meet underserved markets, the Company has made investments in non-opioid pain management and is currently conducting preclinical development of multiple therapeutic, vaccine and diagnostic product candidates utilizing its proprietary platforms for the potential treatment, prevention, and detection of COVID-19 and SARS-CoV-2.
Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVIDTRAP™, ACE-MAB™, COVI-MAB™, COVI-GUARD™, COVI-SHIELD™, and T-VIVA-19™.
REASONS TO BE BULLISH ON SORRENTO STOCK
We are going to try and spell into out for the bears on why it’s suicidal to be short Sorrento stock. Unfortunately, we cannot use small words that they would understand with their limited intellect, but we will try.
First, the key to understanding Sorrento stock is realizing that at its heart, it’s an antibody company. An antibody is a protective protein produced by the immune system in response to the presence of a foreign substance. Cancer cells, bacteria, and viruses, like the one that causes COVID-19, are foreign substances and therefore, theoretically can be impeded or neutralized by antibodies. A vaccine is meant to safely expose a person’s body to a pathogen to teach it to create these neutralizing antibodies. Sorrento’s approach skips the need to teach the body and introduces the neutralizing antibodies directly in vivo. This allows the approach to be administered to healthy and infected people alike.
Second, Sorrento stock is acquiring Cambridge, MA-based SmartPharm Therapeutics, a developer of non-viral DNA and RNA gene delivery platforms for COVID-19 and rare diseases. The company plans to accelerate the development of multiple candidates for in vivo gene-encoded expression of Sorrento antibodies, starting with COVID-19 “cure” STI-1499. It says SmartPharm’s Gene Mab platform enables intramuscular delivery of low-immunogenic DNA plasmid-encoded with a therapeutic antibody for long-lasting expression.
Third, Sorrento stock has a licensing pact with Columbia University for the rights to a rapid one-step diagnostic test that detects the SARS-CoV-2 virus in as little as 30 minutes from a saliva sample. The test developed by Columbia’s team, to be marketed by Sorrento under the COVI-TRACE name, holds all of the testing materials in a single tube and requires no specialized laboratory equipment, making it easily deployable for point-of-care, on-site, or potentially at-home testing.
Fourth, its COVI-TRACK test could drive substantial upside. In order to conduct analytical validation, sample cohorts from healthy donors and COVID-19 patient samples were tested, with the assay showing specificity of over 97% and diagnostic sensitivity of more than 94%. Upon issuance of an EUA, the COVI-TRACK test will be available for distribution to clinical testing sites nationwide. Sorrento has secured manufacturing capacity to support the production of up to five million test kits per month.
Fifth, SRNE has evaluated billions of antibodies and identified a small group that can block the S1 protein’s interaction with human angiotensin-converting enzyme 2 (ACE2), the receptor used for viral entrance into human cells. The hope is that the cocktail will remain effective even if the virus mutates.
Sixth, Sorrento plans to accelerate the development of multiple candidates for in vivo gene-encoded expression of Sorrento’s antibodies, starting with Sorrento’s previously announced STI-1499, or COVI-GUARD, which is currently moving through preclinical and manufacturing requirements with an IND submission targeted for this month.
Seventh, the company’s stake in ImmuneOncia, a clinical-stage immuno-oncology-centric biopharmaceutical company established in 2016 as a joint venture company between Yuhan and Sorrento Therapeutics. Last month, Samsung Biologics (207940.KS) and ImmuneOncia Therapeutics have a partnership to develop and manufacture five candidate molecules, expanding upon the two companies’ existing CDO partnership first established in 2018.
Eighth, Sorrento Therapeutics has turned down at least three takeover offers that we are aware of.
Ninth, the shorts are short 24% of the float or $1 billion at today’s prices. The short squeeze will continue as the shorts cannot withstand losses in the billions.
Tenth, Chairman, CEO, and President Henry Ji, Ph.D. just pulled an Elon Musk and is set for a huge payday. He will earn options to purchase up to ~24.9M shares at $17.30 representing a 10% stake in the company if fully exercised. The award vests in 10 equal tranches starting with ~2.5M options if the company’s market cap reaches $5B. The 10th and last tranche vests if the company’s value hits $35B. Assuming full vestment and no further equity offerings, his total award will be potentially worth ~$3.3B.
Eleventh, Wall Street analysts remain bullish. H.C. Wainwright has a price target of $30 on Sorrento stock and Dawson James has a $24 target. We expect these price targets to keep getting raised as Sorrento stock looks set to continue its bull run.
BOTTOM LINE
These are just eleven reasons off the top of our head that we can think of on why to be bullish on Sorrento stock. However, we left out the biggest one and one which we believe is highly likely – funding from Operation Warp Speed. Funding from the U.S. government would send Sorrento stock flying and put the company on the fast track to commercialization. We believe this is where things are heading and why Chairman, CEO, and President Henry Ji, Ph.D. has no issues taking options at $17.30 a share. He realizes that even with the tremendous run we’ve seen in Sorrento stock so far this year, the rally could just be getting started.
As always, good luck to all (except the shorts)
Sorrento owns 100% of SmartPharm: Here's how "Gene MAbs™ work for Coronavirus
"SmartPharm is applying our non-viral gene therapy platform to develop an effective preventive treatment for SARS-CoV-2. We are using DNA designed to produce in the muscle of the person who receives the gene a monoclonal antibody (“Gene Mab™”) that could be protective against the SARS-CoV-2 virus. To do this, we are utilizing a novel DNA vector with low immunogenicity, durable expression potential and cost-effective manufacturing up to millions of doses. We are coupling this type of DNA vector with a delivery system that significantly enhances DNA expression in the muscle and is also capable of high-volume, economic production. Coupled together, these represent a way to generate protective mAbs in many people to provide “pop-up immunity” in this population against COVID-19 regardless of their immune status or their infection status.
The first step in developing a Gene MAb™ against SARS-CoV-2 is to determine a mAb sequence that possesses both a high binding affinity to the coronavirus (so it stays attached to the virus for a long time) and the ability to neutralize the virus (block it from invading cells or attract immune response against the virus). We have implemented strategic partnerships with a number of organizations to do this, including Sorrento Therapeutics. Sorrento has initiated an accelerated program to identify potent neutralizing antibodies against SARS-CoV-2 that can be used for either treatment or prophylaxis(eg 1499). Based on this collaboration as well as internal work, SmartPharm will define a DNA that can express these antibodies in human skeletal muscle and use a delivery technology designed to allow the DNA to be delivered directly into the muscle. The SmartPharm delivery system is designed to be used with a standard hypodermic needle, the way most vaccines are delivered.
1. Antibodies with significant neutralizing efficacy against SARS-CoV-2 are identified in recovered COVID-19 patients. 2. The antibody is sequenced and incorporated into a DNA plasmid. 3. Plasmids are combined with a delivery system for a final formulation of the Gene MAb™ drug. 4. The Gene MAb™ is given to people using a standard hypodermic injection.
After delivery in the muscle, the DNA is designed to produce antibodies in the muscles within a matter of hours. Within a day or two—a much faster time than a typical vaccine—protective levels of antibody could be produced, resulting in what we refer to as “pop up-immunity”: a rapidly-established window of immune protection against the virus.
Antibody production lasts a number of weeks or even months and is effective regardless of what the recipient’s immune system is like or whether they are infected or not. Creating pop-up immunity with Gene MAbs™, which are both cost-effective and scalable for large population protection, introduces a way to quickly mount a protective immune barrier in treated people and reduce the infectivity of the virus in larger populations."
The same technology can be applied to enzyme replacement therapy, heart disease and cancer! Multi-blockbuster potential.
That is a great post and it reminds us that Sorrento is aiming to have THE BEST-IN-CLASS test, antibody and vaccines. Others will be first but with poor tests, antibodies and vaccines. That is already happening. It is THE BEST-IN-CLASS who will prevail!
The exciting SmartPharm acquisition is complete. September will be busy!
1. COVI-TRACK 8 minute antibody test kit approval and marketing partnership
2. COVI-TRACE 30 minute virus saliva test kit approval(US and Brazil)
3. Celularity reports good interim phase 1/2 results (Sorrento owns 25%)
4. COVI-GUARD single antibody enters clinic(US and Brazil)
5. COVI-SHIELD triple antibody enters clinic
6. T-VIVA-19 vaccine enters clinic
7. Abivirtinib cytokine storm trial phase 2 enters clinic(US and Brazil)
8. Preclinical, peer reviewed data publication on STI-1499 and STI-4398 from UTMB, Dr. Slobodan Paessler (anytime now).
9. Sorrento/SmartPharm antibody vaccine enters clinic
10. Federal grants $500+ million
11. PSS decides to agree to $1.2 billion out of court settlement
12. Analysts upgrade from current $24 price target (DONE.) Now $30 and rises as each catalyst is announced)
Nasdaq and Dow down over 400 points. I follow 20 biotechs...all down today. Buying opportunity for many biotechs! Buffet will be buying today! There's a lot of great news for Sorrento coming this month from FDA and Brazil. Covid isn't going away any time soon. Nor is cancer or chronic pain...Sorrento has the goods!
Thanks Jess. Very interesting. It may be both storms.
"Jacobson’s team says in their paper that “the pathology of Covid-19 is likely the result of Bradykinin Storms rather than cytokine storms,” which had been previously identified in Covid-19 patients, but that “the two may be intricately linked.” Other papers had previously identified bradykinin storms as a possible cause of Covid-19’s pathologies."
Another case where combination therapy will be required !
Oral Abivertinib to fight cytokine storm will be in the clinic in the US within days...and will soon be in the clinic in Brazil. It is phase 2 because its safety was established in over 600 cancer patients. It has had very good results in NSCLC and might be a good combination with CAR-T to prevent cytokine storm in cancer patients.
- Confirmed rumored Brazil deal is real
- Paid just under $20M for SmartPharm - saved our cash for paying off debt and SmartPharm was willing to take our stock instead of cash which says a lot about where they think the SP is going.
- Expects SmartPharm deal to yield multiple billions or even double digit billions
- No debt vs lies being told by shorts
- His goal is to get to $100-200 Billion within 5 years
- Working closely with FDA - multiple items in pipeline are in various stages with FDA approvals and they are very happy with how things are going.
- Just getting to a $25B market cap should bring close to a $100 share price
New September 2020 Corporate Presentation.
https://investors.sorrentotherapeutics.com/static-files/fd779b28-01b8-4e9b-b01b-41bd2c00d933
And they are aiming to build a company with a "$100-200 Billion market cap."...eg another Pfizer! With FDA and Brazilian approvals coming soon on Covid trials and growing cancer and non-opioid pain portfolios this is early days in a very dynamic company!
Sign up here for the Sept.3 LD MICRO online Conference at 12:40 ET or 9:40 PT.
https://www.webcaster4.com/Webcast/Page/2019/36795
The synergy between the SmartPharm technology and Sorrento's billion monoclonal antibody library is amazing. Covid is only the beginning ... think of the application to future pandemics, a wide variety of cancers and inflammatory diseases. Using the patients own body as the antibody factory lowers costs and dramatically extends the duration of treatment. In the big picture this could increase the value of Sorrento tenfold!
If we hear about COVI-TRACK approval, COVI-GUARD (1499) entering the clinic and ABIVERTINIB phase 2 trial startup all in one week the share price could move to $20+.All are due.
Sorrento's 1499 antibody injections appear to be able to clear out the Covid virus in a few days at a very low and safe dose. The results from Brazil trials could be remarkable.
On the other hand some of the earliest attempts by other companies to produce vaccines are running into problems. Some have production, transportation and storage difficulties. Others simply have significant negative side-effects. A recent article stated..."A COVID-19 vaccine developed by Oxford University and the drug giant AstraZeneca elicited side effects such as fever, headaches, muscle aches, and injection site reactions in about 60% of patients, according to American health news website Stat. Some manufacturers such as Moderna, based in Massachusetts, and CanSino Biologics, based in China, have stopped testing the highest doses of COVID-19 vaccines due to the number of severe adverse events recorded among participants, Stat reported."
COVI-GUARD (1499)to clear the virus and Abivirtinib to prevent cytokine storm have enormous potential.
.
Every once in awhile I look at stocktwits. Here's an intriguing post speculating on what's been going on behind the news blackout.
"Here is what I suspect Ji has been hiding from us. 1) Phase 1 trials of STI-1499 begin Monday in Brazil. 2) FDA submission of the spit test. 3) Agreed upon merger stock price of $9-11/share with SmartPharma. 4) Abivertinib non-COVID application Phase 3 trial ended with potential on-market date announcement. 5) Abivertinib COVID applications submitted to FDA approval to start phase 3 trials for COVID applications no later than September 15th. 6) Increased earnings figures may indicate contracts with Abivertinib?"
Next week should be fun.
Sorrento is aiming to have the BEST vaccine. Some of the FIRST vaccines have serious issues.
https://www.marketwatch.com/story/moderna-and-pfizers-covid-19-vaccine-candidates-require-ultra-low-temperatures-raising-questions-about-storage-distribution-2020-08-27
Thoughtful post from Ted on Yahoo!
"Adding a few points that I don't see discussed much:
1. SRNE acquisition of SmartPharm is much underappreciated by the market. It's like Tesla buying the best lithium battery technology while others are still playing with nickel-cadmium. This accretive investment creates strong synergy of two best technologies, benefiting SRNE's entire antibody pipeline.
2. STI-1499 starting in vivo trials is a statement of confidence and promising outlook. Don't forget the new STI-2020dna. If STI-1499 is great then STI-2020dna incorporating gene-encoded delivery will be amazing.
3. No need to fear more approved testing products coming to market. Research and know the superior technology behind COVI-TRACE. Who still talks about Yale's testing that was such a hype a short while ago? ABT will end up in the same bucket more or less. Keep in mind the COVID testing market is incredibly huge – $45 billion and growing. I SMH when people reacted as if SRNE was just a testing company with 1 mediocre product.
4. SRNE have been increasingly mentioned by renowned medical journals and general media around the world, often next to the big names.
5. In an interview on COVID antibody treatments, a doctor specifically mentioned Sorrento, not Regeneron or Eli Lilly, which both ran into issues and now expect major delays for their antibody trials.
6. Brazil card is a super smart play by Henry both for easier/faster patient recruits and to de facto put FDA on notice for foot-dragging and favoritism.
The more I research into SRNE, the more I'm impressed by its mission and ability to pursue best-in-class, cutting-edge products backed by its own top scientists and worldwide resources/collaboration. Henry is a visionary scientist and smart deal maker, and I'm convinced there's more amazing stuff up his sleeve. What's coming out next would completely revolutionize how viruses can be detected and risk assessed to help save numerous industries and reopen economy at large. Shorts can keep playing their game but once the PR wave arrives to wow the world, all shorts big and small will be buried. SP will return to $20 and hit $30 sooner rather than later. Always keep in mind investing is long term and will have ups and downs. GLTA longs."
ABIVERTINIB TRIAL fighting cytokine storm is announced. Here is what an article says...
"Abivertinib has two applications. It is being scrutinized as an immunotherapy in non-small cell lung cancer (NSCLC). It is currently in Phase 3 clinical testing. This is interesting and perhaps a compelling reason to purchase SRNE shares in and of itself.
Yet that is not why we are here. Markets are interested in its Covid-19 application.
Abivertinib is being evaluated in regard to its ability to combat cytokines and the so-called cytokine storm in Covid-19. According to New Scientist, a cytokine storm is a severe reaction to infection leading to inflammation which can be fatal. Scientists believe the cytokine storm phenomenon is what causes death in Covid-19. Thus, Sorrento can potentially play the hero if it can solve the cytokine response issue.
Let’s assume that Abivertinib gains FDA approval for both its cancer and Covid-19 applications. In this imaginary exercise, Sorrento would surely make a lot of money, sending SRNE stock sky high."
The article quite correctly draws attention to the NSCLC and Covid cytokine storm applications. There is also a third potentially large application. That is to add it as a combination with Car-T cells as their efficacy can be powerful, however frequently accompanied by an undesirable cytokine storm. Abivertinib may contribute to both efficacy and safety...a third very large market.
Dr.Ji warned shorters. Newsflow is coming over next couple of weeks! Many of these events will occur!
1. COVI-TRACK 8 minute antibody test kit approval and marketing partnership
2. COVI-TRACE 30 minute virus saliva test kit approval
3. Celularity reports good interim phase 1/2 results (Sorrento owns 25%)
4. COVI-GUARD single antibody enters clinic
5. COVI-SHIELD triple antibody enters clinic
6. T-VIVA-19 vaccine enters clinic
7. Abivirtinib cytokine storm trial PHASE 2 enters clinic
8. Preclinical, peer reviewed data publication on STI-1499 and STI-4398 from UTMB, Dr. Slobodan Paessler (anytime now).
9. Sorrento/SmartPharm antibody vaccine enters clinic
10. Federal grants $500+ million
11. PSS decides to agree to $1.2 billion out of court settlement
12. Analysts upgrade from current $24 price target (DONE.) Now $30 and rises as each catalyst is announced)
13. Institutional buying continues
14. Insiders own 34%!
Convolescent plasma is 35% effective.."not a home run"!
Sorrento antibody 1499 is 100% effective so far..."home run"?
"Results of the study by the Mayo Clinic that the FDA cited in its authorization of the plasma treatment indicates that patients below age 80 who were not on a respirator and received plasma with a high level of antibodies within three days of diagnosis were about 35% more likely to survive another 30 days compared with patients who received plasma with a low level of antibodies.
The study acknowledged, however, that its findings are limited, particularly because it did not have a placebo comparison.
Dr. Scott Gottlieb, a former FDA commissioner, said the treatment might help patients but it “doesn’t look like a home run.” He did agree that convalescent plasma “certainly” met the standard for an emergency use approval “in the setting of a public health emergency.”
“I think that this could be beneficial. It might be weakly beneficial,” Gottlieb said on “Squawk Box.” “It doesn’t look like a home run, but right now we’re looking for singles and doubles. There aren’t really going to be any home runs on the horizon until we can get the OTHER THERAPEUTIC ANTIBODIES on the market and hopefully eventually vaccines and better therapeutics.”
SORRENTO'S 1499 IS THE BABE RUTH OF ANTIBODIES!
30 Reasons why my price target is $100+
1. PSS lawsuit worth $1.2 Billion+ potential
2. BARDA funding, other government funding
3.CYNK-001 NK FDA Phase 1/Phase 2 Trial data with Celularity (Sorrento has 25% stake)
4. STI-4398 (COVIDTRAP) FDA Phase 1 clinical trial
5. STI-1499 (COVIGUARD)FDA IND approval
6. COVISHIELD(Therapeutic cocktail in partnership with Mt. Sinai Hospital) FDA IND application
7. Preclinical, peer reviewed data publication on STI-1499 and STI-4398 from UTMB, Dr. Slobodan Paessler (anytime now).
8. I-Cell COVID 19 Vaccine IND approval
9. Sorrento and SmartPharm gene encoded vaccine IND application
10. Sorrento and MabPharma ACE MAB IND approval
11. Phase 1 trial data of CD 38 for Amyloidosis
12. SP-102 phase 3 results
13. CD38 lymphoma IND
14. RTX arthritis news
15. RTX knee pain news
16. RTX cancer pain news
17. RTX ARDS treatment
18. Scilex potential IPO
19. FDA approval of COVI-TRACK
20. Sales begin for COVI-TRACK
21. Several cancer trials with first-in-class DAR-T are coming
22. Abivirtinib phase 2 in Covid begins in August
23. Water soluble CBD partnership
24. Covid T-VIVA-19 Vaccine enters clinic
25. COVI-TRACE saliva test enters clinic
26. COVI-TRACE gains approval
27. SOFUSA delivery phase 1b cancer trial
28. Analysts target prices are increasing steadily. $30 is latest
29. Institutions are buying. Up from 18% to 26% this week alone
30. Insiders holding solid at 34%
Sorrento is increasingly being seen as a leader in Covid, non-opioid pain and cancer technologies. It is a small pharma with a large pharma portfolio. There's a lot of room for partnerships and growing value for a buyout. Big pharmas with emptying portfolios will be attracted by a fistful of potential blockbusters!
I'm very impressed by the great potential from combining Sorrento's antibodies with SmartPharms technology. Here's a link to an October 2019 SmartPharm presentation which demonstrates the sophistication of their approach. This shows the huge potential of what they were working on BEFORE Sorrento started working with them.
https://smartpharmtx.com/archives/5338